New Agents and Evolving Strategies in Prostate Cancer: Focus on Castration-Sensitive Disease

Register now for this interactive satellite symposium held in conjunction with the 2022 Genitourinary Cancers Symposium in San Francisco to hear about the recent advances in the use of androgen-deprivation therapy for patients with castration-sensitive prostate cancer. After the meeting, view the on-demand webcast and download the associated slideset for use in your clinic.

Not an official event of the 2022 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.


Welcome and Introduction

Defining Castration Sensitivity in Metastatic and Nonmetastatic Prostate Cancer

Mechanism of Action and Comparisons of the Safety Profiles of Currently Available Androgen-Deprivation Therapies for Castration-Sensitive Prostate Cancer (CSPC)

Insights for Individualizing Treatment Options for Patients with CSPC

New Agents and Evolving Strategies in CSPC

Case Discussions Including Healthcare Professional-Patient Engagement Strategies

Key Takeaways and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Michael S. Cookson, MD, MMHC, FACS

Professor and Chair
Department of Urology
The University of Oklahoma Health Sciences Center, College of Medicine
Urologic Oncologist
OU Health Stephenson Cancer Center, Prostate & Urologic Cancers Clinic
OU Health
Oklahoma City, Oklahoma

Atish Choudhury, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Senior Physician
Medical Oncology
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

David F. Jarrard, MD

Professor and Vice Chair
Department of Urology
John P. Livesey Chair in Urologic Oncology
Associate Director for Translational Research
Carbone Cancer Center
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with prostate cancer.

Target Audience
This program is intended for oncologists and other healthcare professionals who care for patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Compare the mechanism of action, cardiovascular risk, and overall toxicity profiles associated with all approved systemic therapies for CSPC
  • Apply cardioprotective strategies to reduce risk in patients with prostate cancer receiving ADT
  • Plan optimal, individualized sequential therapeutic strategies for nonmetastatic or metastatic castration-sensitive prostate cancer, considering all available agents, clinical data, and expert recommendations
  • Counsel patients on available therapies, taking into consideration patient preferences and comorbidities regarding differences in administration and safety profiles


       Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.